Akebia Receives FDA Acceptance Of Resubmission To NDA Of Vadadustat For The Treatment Of Anemia Due To Chronic Kidney Disease
March 27, 2024 Set as User Fee Goal DateAkebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the U.S. Food